Abdera Therapeutics, Inc.
🇨🇦Canada
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Phase 1
Recruiting
- Conditions
- Small-Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Abdera Therapeutics Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT06736418
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸United Theranostics, Glen Burnie, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath